GE Healthcare commends DEA decision that will make DaTscan™ (Ioflupane I 123 Injection) more available to patients who may have Parkinsonism

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

GE Healthcare (NYSE:GE) is pleased to announce that the US Drug Enforcement Administration (DEA) has removed the compound ioflupane I 123 from the schedules of the Controlled Substance Act, which has resulted in the descheduling of DaTscan™ (Ioflupane I 123 Injection).